Syngene International Limited has informed the Exchange regarding Board meeting held on July 23, 2025.
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Smallcap 250 and 1.6 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syngene International reported its Q1 FY26 results with consolidated revenue from operations at Rs 7,897 million, down about 9.7% from Rs 8,745 million in Q1 FY25. Standalone revenue fell similarly to Rs 7,265 million from Rs 7,993 million. Consolidated profit after tax slipped to Rs 757 million from Rs 867 million, a roughly 12.7% drop, while standalone PAT was flat at Rs 740 million. Consolidated basic EPS came in at Rs 1.89 versus Rs 2.16 a year ago. The Board also recommended a final dividend of Rs 1.25 per share subject to shareholder approval, and confirmed an allotment of 402,439 shares to the Syngene Employees Welfare Trust under the long-term incentive plan. The auditor (B S R & Co. LLP) issued unqualified limited review reports on both standalone and consolidated results.
A notable year-on-year revenue and profit decline may weigh on near-term sentiment, though the flat standalone PAT and stable margin profile suggest the softness is largely volume-led. The dividend and capacity expansion updates are mildly positive, but investors will likely focus on the revenue contraction when assessing the stock.